Riva Therapeutics
Joe Markson currently serves as Principal at Novo Holdings since June 2020, following roles as Senior Associate and Associate in Venture Investments. Markson is also a Board Observer for Hummingbird Bioscience and previously for Reneo Pharmaceuticals, contributing from Novo Ventures' Series B investment through Reneo's IPO. Additionally, Markson holds a Directorship on the Board of Directors for Riva Therapeutics and serves as a Board Observer for Ray Therapeutics, both from 2023. Prior experience includes positions at 10x Genomics and twoXAR Pharmaceuticals focusing on strategy and portfolio management, respectively. Markson's earlier career includes consulting at The Boston Consulting Group, specializing in healthcare, and postdoctoral research at Caltech and Harvard University. Academic qualifications include a PhD in Biophysics and an MPhil in Chemistry from Harvard University, along with an AB in Biochemical Sciences.
This person is not in the org chart
This person is not in any teams
Riva Therapeutics
Riva Therapeutics is a precision oncology company focused on creating transformative medicines for cancer patients. We are developing a new generation of small molecule therapeutics by leveraging deep knowledge of genomic dependencies to selectively target essential tumor cell processes beyond DNA damage repair. Our precision lethal therapies have the potential to provide profound clinical activity, be well-tolerated, and substantially improve patient lives. For more info: https://rivatherapeutics.com/